本帖最后由 老马 于 2012-1-13 21:20 编辑 8 {$ }8 }( a1 F4 M# X
& ]1 {$ o/ _, b
爱必妥和阿瓦斯丁的比较
0 n. R! ] r( l0 F
# @( G' Z2 N, W% _- Bhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/
3 F( x% o/ c* i8 Q* `6 D
( u- |& Y- R, @1 u, V4 Y$ H
( V) z# \- S' v& j5 X9 X1 T! rhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
) U3 D! G: O. H# C==================================================0 B, {. j" M8 N* L4 q4 \. ~
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)9 u+ A1 C5 H6 S: o
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
. q x9 b$ M- ~/ iResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
7 N6 G5 o/ \# \" a- i5 ?
|